http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Invitae Executive Appointed to National Health Information Technology Advisory Committee
-
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
-
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing
-
InVitae (NVTA) Announces Collaboration with Worldwide Clinical Trials to Accelerate Trials for Rare Disease Patients
-
Worldwide Clinical Trials Enters Into a Strategic Collaboration With Invitae to Accelerate Clinical Trials for Rare Disease Patients
-
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board
-
Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress
-
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
-
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
-
InVitae (NVTA) to Combine with ArcherDX
-
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
-
Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
-
Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
-
Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
-
Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders
-
Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
-
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
-
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
-
Invitae expands network of patients in rare and ultra-rare diseases
-
Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information
-
Invitae expands existing credit facility to provide up to $40.0 million in available growth capital
-
Invitae to present at the Cowen and Company 38th Annual Health Care Conference
-
Invitae reports over 150% volume and over 170% revenue growth for 2017
-
Safeguard Scientifics Announces Third Quarter 2017 Financial Results
-
Safeguard Scientifics Partner Company Good Start Genetics To Be Acquired By Invitae Corporation
-
Invitae Announces First Quarter 2016 Financial Results
-
Invitae to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on February 9, 2016
-
Invitae Announces It Met Volume Guidance by Delivering Nearly 19,000 Billable Tests in 2015 and Sets Volume Guidance at 50,000-70,000 Billable Tests for 2016
-
Invitae Announces Expansion of Its Epilepsy Test Menu
-
Invitae Announces Expansion of Hereditary Cancer Testing Menu
-
Invitae Announces Third Quarter 2015 Financial Results and Raises 2015 Volume Guidance
-
Invitae Appoints Christine M. Gorjanc to its Board of Directors
-
Invitae to Provide Testing for Sudden Death in the Young (SDY) Case Registry to Advance Understanding of Sudden Death in the Young
-
Invitae to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
-
Invitae Expands Its Cardiology Offering to Provide More Comprehensive Testing for Patients and Their Families
-
Invitae Expands Its Hereditary Cancer Offering
-
Invitae Expands Its Neuromuscular Offering with Broad, Affordable Panels and New Testing Categories for Patients
-
Invitae Expands Its Offering for Rare Disease and Pediatric Conditions with Broader, Affordable Genetic Tests
-
Invitae Expands Test Menu to Include Hundreds of New Genes, Dozens of New Test Panels for Cancer, Cardiology, Neuromuscular, Pediatrics, and Rare Disorders
-
Invitae to Host Investor Conference Call on October 7, 2015 to Discuss Expanded Genetic Testing Menu
-
Invitae Announces New Education Program to Accelerate the Use of Family History and Increase Awareness of Genetic Testing
-
Invitae announces new education program to accelerate the use of family history and increase awareness of genetic testing
-
Invitae to Present at the 2015 Morgan Stanley Global Healthcare Conference
-
Invitae and Collaborators Announce Publication of New Data Showing the Clinical Actionability of Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer Risk in JAMA Oncology
-
Invitae Raises Volume Guidance, Announces Second Quarter 2015 Financial Results
-
Invitae to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Invitae to Announce Second Quarter 2015 Financial Results and Host Conference Call on August 6, 2015
-
Invitae Announces Online Publication of Data Comparing Traditional and Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer in The Journal of Molecular Diagnostics
-
Invitae Launches New Patient Pay Price of $475 for Its Full Menu of Genetic Tests
-
Invitae and Collaborators to Present New Data at the 2015 American Society of Clinical Oncology Annual Meeting Focusing on the Clinical Utility of Multi-Gene Panel Tests for Hereditary Breast and Ovar
